{
  "symbol": "MRKR",
  "company_name": "Marker Therapeutics Inc",
  "ir_website": "https://ir.markertherapeutics.com/",
  "structured_data": [
    {
      "section_name": "News & Events",
      "links": [
        {
          "title": "Press Releases",
          "url": "https://ir.markertherapeutics.com/news-events/press-releases",
          "content": "[ Skip to main navigation ](#main-menu)\n\n  * [Contact Us](https://markertherapeutics.com/our-company/contact-us/)\n  * [](https://twitter.com/intent/tweet?text=Our Company http://newsite.markertherapeutics.com/our-company/overview/ \"Tweet This\")\n  * [](https://www.linkedin.com/company/marker-therapeutics \"Connect on LinkedIn\")\n\n\n\n![About Marker Therapeutics](/sites/g/files/knoqqb58336/themes/site/nir_pid3888/dist/images/subpage-header-ir-min.jpg)\n\nInvestors/Media\n\nPress Releases\n\n# Press Releases\n\nYear None2024202320222021202020192018\n\nNone\n\nNov 26, 2024 \n\n[Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit](/news-releases/news-release-details/marker-therapeutics-present-citizens-jmp-hematology-and-oncology)\n\nNov 14, 2024 \n\n[Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates](/news-releases/news-release-details/marker-therapeutics-reports-third-quarter-2024-financial-results)\n\nAug 14, 2024 \n\n[Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates](/news-releases/news-release-details/marker-therapeutics-reports-second-quarter-2024-financial)\n\nAug 12, 2024 \n\n[Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin’s Lymphoma](/news-releases/news-release-details/marker-therapeutics-awarded-2-million-grant-nih-support-phase-1)\n\nMay 15, 2024 \n\n[Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates](/news-releases/news-release-details/marker-therapeutics-reports-first-quarter-2024-financial-results)\n\nApr 08, 2024 \n\n[Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies](/news-releases/news-release-details/principal-investigator-city-hope-national-medical-center-invited)\n\nMar 25, 2024 \n\n[Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results](/news-releases/news-release-details/marker-therapeutics-reports-year-end-2023-corporate-and)\n\nMar 22, 2024 \n\n[Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference](/news-releases/news-release-details/marker-therapeutics-present-hc-wainwright-2nd-annual-cell)\n\nJan 22, 2024 \n\n[Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601](/news-releases/news-release-details/marker-therapeutics-receives-approval-united-states-adopted-name)\n\nJan 08, 2024 \n\n[Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization](/news-releases/news-release-details/marker-therapeutics-announces-clinical-program-updates-and-0)\n\nDisplaying 1 - 10 of 105 \n\n[](#top \"Back to Top\")\n"
        },
        {
          "title": "Events & Presentations",
          "url": "https://ir.markertherapeutics.com/news-events/events-presentations",
          "content": "[ Skip to main navigation ](#main-menu)\n\n  * [Contact Us](https://markertherapeutics.com/our-company/contact-us/)\n  * [](https://twitter.com/intent/tweet?text=Our Company http://newsite.markertherapeutics.com/our-company/overview/ \"Tweet This\")\n  * [](https://www.linkedin.com/company/marker-therapeutics \"Connect on LinkedIn\")\n\n\n\n![About Marker Therapeutics](/sites/g/files/knoqqb58336/themes/site/nir_pid3888/dist/images/subpage-header-ir-min.jpg)\n\nInvestors/Media\n\nEvents & Presentations\n\n# Events & Presentations\n\nPresentations \n\n[Corporate Presentation](/static-files/8b2e9657-4d9d-4e1d-86cb-0e49d07e38dc)\n\nAug 16, 2024\n\n[Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data Supporting the MT-401 Off-the-Shelf Program](/static-files/883357c7-3b86-40db-98bd-55f9608c7ad9)\n\nAug 07, 2023\n\n[Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration](/static-files/1af66d9a-8230-4be3-90f5-2fbad6474df9)\n\nJun 26, 2023\n\n[Marker Therapeutics Announces Pre-Clinical Data of MT-601 in Lymphoma Cells](/static-files/7fcd0b1d-9d85-4cce-9477-c21c058fea87)\n\nMay 31, 2023\n\n## Videos\n\n[Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data Supporting the MT-401 Off-the-Shelf Program](https://youtu.be/2tt8es_dea0)\n\nUpcoming Events \n\nThere are no upcoming events available at this time. \n\nPast Events \n\n[H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference Presentation](/events/event-details/hc-wainwright-2nd-annual-cell-therapy-virtual-conference)\n\nMar 26, 2024 at 10:00 AM EDT \n\n[CLICK HERE FOR WEBCAST](https://journey.ct.events/view/3b63b782-6942-4a75-bc3c-467af48e0ab2)\n\n[H.C. Wainwright 25th Annual Global Investment Conference](/events/event-details/hc-wainwright-25th-annual-global-investment-conference)\n\nSep 13, 2023 at 8:30 AM EDT \n\n[CLICK HERE FOR WEBCAST](https://journey.ct.events/view/5f505fae-5fbc-4a22-964d-59232c33372d)\n\nLocation\n\nKennedy I\n\n[KOL Expert Webinar: Beyond CAR-T, What’s Next for Cell Therapy](/events/event-details/kol-expert-webinar-beyond-car-t-whats-next-cell-therapy)\n\nAug 9, 2023 at 11:00 AM EDT \n\n[Click here for webcast](https://web.cvent.com/event/d7b7a2d7-e892-4876-9924-7020190fa2b7/regProcessStep1?_hsenc=p2ANqtz-9UmfueSqPkFCbiXG4ARSLl6v1TGgRXMTcdL5dWRj-VDbAEXeJAbKIHEry3sC2BTO9yMc-vZ2ceubgQm6KJVNIyWASMJw&_hsmi=267259723&utm_campaign=Virtual%20Salons&utm_content=267259723&utm_medium=email&utm_source=hs_automation)\n\n[Cantor Fitzgerald Cell and Genetic Medicines Conference](/events/event-details/cantor-fitzgerald-cell-and-genetic-medicines-conference)\n\nSep 15, 2022 at 9:20 AM EDT \n\n[33rd Annual Cancer Progress Conference](/events/event-details/33rd-annual-cancer-progress-conference)\n\nMay 12, 2022 at 2:00 PM EDT \n\n[Oppenheimer Virtual Annual Healthcare Conference](/events/event-details/oppenheimer-virtual-annual-healthcare-conference)\n\nMar 17, 2022 at 10:40 AM EDT \n\n[ROTH Annual Conference](/events/event-details/roth-annual-conference)\n\nMar 14, 2022 at 11:00 AM EDT \n\n[Click here for webcast](https://wsw.com/webcast/roth43/mrkr/1846896)\n\n[Marker Therapeutics Clinical Program Update ](/events/event-details/marker-therapeutics-clinical-program-update)\n\nFeb 16, 2022 at 5:00 PM EST \n\n[Click here for webcast](https://event.webcasts.com/starthere.jsp?ei=1528404&tp_key=d58a8577ea)\n\nSupporting Materials\n\n[Clinical Program Updates and Pipeline Expansion](/static-files/e077386d-de55-4227-b513-1052d1a69997 \"Marker Clinical Updates and Pipeline Expansion Presentation_16Feb2022.pdf\") 3.6 MB\n\n[Cantor Fitzgerald Global Healthcare Conference](/events/event-details/cantor-fitzgerald-global-healthcare-conference)\n\nSep 27, 2021 at 10:40 AM EDT \n\n[Click here for webcast](https://wsw.com/webcast/cantor12/mrkr/2105880)\n\n[Oppenheimer Fall Healthcare Life Sciences & MedTech Summit](/events/event-details/oppenheimer-fall-healthcare-life-sciences-medtech-summit)\n\nSep 22, 2021 at 9:05 AM EDT \n\n[Click here for webcast](https://wsw.com/webcast/oppenheimer16/mrkr/2808276)\n\n[](#top \"Back to Top\")\n"
        }
      ]
    },
    {
      "section_name": "Financials & Filings",
      "links": [
        {
          "title": "SEC Filings",
          "url": "https://ir.markertherapeutics.com/financials-filings/sec-filings",
          "content": "[ Skip to main navigation ](#main-menu)\n\n  * [Contact Us](https://markertherapeutics.com/our-company/contact-us/)\n  * [](https://twitter.com/intent/tweet?text=Our Company http://newsite.markertherapeutics.com/our-company/overview/ \"Tweet This\")\n  * [](https://www.linkedin.com/company/marker-therapeutics \"Connect on LinkedIn\")\n\n\n\n![About Marker Therapeutics](/sites/g/files/knoqqb58336/themes/site/nir_pid3888/dist/images/subpage-header-ir-min.jpg)\n\nInvestors/Media\n\nSEC Filings\n\n# SEC Filings\n\nGroup 3,4,5Annual FilingsCurrent ReportsMergers & AcquisitionsOtherProxy FilingsQuarterly FilingsRegistration Statements\n\nFiling year - Any -20242023202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999\n\n- Any -\n\nItems per page 102550\n\n10\n\n[Filing date ](?items_per_page=10&order=field_nir_sec_date_filed&sort=asc \"sort by Filing date\") | [Form](?items_per_page=10&order=field_nir_sec_form&sort=asc \"sort by Form\") | [Description](?items_per_page=10&order=field_nir_sec_description&sort=asc \"sort by Description\") | View  \n---|---|---|---  \nNov 27, 2024 | [S-3](/sec-filings/sec-filing/s-3/0001104659-24-123679) | Simplified registration form |  [0001104659-24-123679.pdf](/static-files/8d388a3b-b320-49ac-837f-667bff8835d1) [0001104659-24-123679.rtf](/static-files/3ab28a36-9c4d-462a-88e2-8f80e2155239) [0001104659-24-123679.xls](/static-files/a80affdc-47a8-4f1e-a765-9c4fc295f940) [View HTML](/node/11151/html)  \nNov 14, 2024 | [10-Q](/sec-filings/sec-filing/10-q/0001410578-24-001978) | Quarterly report which provides a continuing view of a company's financial position |  [0001410578-24-001978.pdf](/static-files/7b2dfc25-3251-4a27-81c6-a163ae95588d) [0001410578-24-001978.rtf](/static-files/27fb3fad-6b6f-4c10-b406-943397542944) [0001410578-24-001978.xls](/static-files/f419dd39-28ae-4615-9a84-7dcc53a26048) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/10-q/0001410578-24-001978) [View HTML](/node/11126/html)  \nNov 14, 2024 | [8-K](/sec-filings/sec-filing/8-k/0001104659-24-119077) | Report of unscheduled material events or corporate event |  [0001104659-24-119077.pdf](/static-files/be7d3317-5da5-4f4e-8913-1f178d1a7200) [0001104659-24-119077.rtf](/static-files/d938388a-a878-4563-897a-b536f8f79fef) [0001104659-24-119077.xls](/static-files/aec2977c-7244-4324-a3f5-16504d0b3266) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/8-k/0001104659-24-119077) [View HTML](/node/11141/html)  \nAug 14, 2024 | [10-Q](/sec-filings/sec-filing/10-q/0001410578-24-001454) | Quarterly report which provides a continuing view of a company's financial position |  [0001410578-24-001454.pdf](/static-files/6d43d158-a2a9-4a6b-b018-cca86795312c) [0001410578-24-001454.rtf](/static-files/85ad361f-139a-445d-9d3c-74d11cf8d09d) [0001410578-24-001454.xls](/static-files/3f3a1ee7-f444-484d-af65-9dbe6541afb7) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/10-q/0001410578-24-001454) [View HTML](/node/11116/html)  \nAug 14, 2024 | [8-K](/sec-filings/sec-filing/8-k/0001104659-24-089704) | Report of unscheduled material events or corporate event |  [0001104659-24-089704.pdf](/static-files/a478252e-20fe-43a5-925e-c0e7e8b9868a) [0001104659-24-089704.rtf](/static-files/3a89b134-ef06-49d0-b629-c368debf15fa) [0001104659-24-089704.xls](/static-files/c05d0967-76f9-47b5-8843-842cb58bef93) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/8-k/0001104659-24-089704) [View HTML](/node/11121/html)  \nAug 12, 2024 | [8-K](/sec-filings/sec-filing/8-k/0001104659-24-088054) | Report of unscheduled material events or corporate event |  [0001104659-24-088054.pdf](/static-files/455ff32f-fb7d-42d1-88a7-00f55920bbb6) [0001104659-24-088054.rtf](/static-files/ebe3a3ba-91d4-477d-bcc6-b3b09ea34517) [0001104659-24-088054.xls](/static-files/daef1b93-03aa-4308-9098-2adbeaa832ab) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/8-k/0001104659-24-088054) [View HTML](/node/11101/html)  \nJun 12, 2024 | [8-K](/sec-filings/sec-filing/8-k/0001104659-24-070830) | Report of unscheduled material events or corporate event |  [0001104659-24-070830.pdf](/static-files/69bd8f32-fe7a-463a-a8d3-1b64ba3c34ca) [0001104659-24-070830.rtf](/static-files/5eb0f14f-48b9-4a71-a575-a58d63dfe9d9) [0001104659-24-070830.xls](/static-files/28aad4e8-fc68-403d-871a-98c15cb2a449) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/8-k/0001104659-24-070830) [View HTML](/node/11076/html)  \nMay 17, 2024 | [SC 13D/A](/sec-filings/sec-filing/sc-13da/0001072613-24-000515) | An amendment to a SC 13D filing |  [0001072613-24-000515.pdf](/static-files/4cc5767b-83f3-4792-b1a1-8f198e527c6c) [0001072613-24-000515.rtf](/static-files/9e0175d6-e0f9-4e8b-88d3-341888b120a3) [0001072613-24-000515.xls](/static-files/803605ce-7d48-495c-b196-0eb99f2ee819) [View HTML](/node/11071/html)  \nMay 15, 2024 | [10-Q](/sec-filings/sec-filing/10-q/0001410578-24-000865) | Quarterly report which provides a continuing view of a company's financial position |  [0001410578-24-000865.pdf](/static-files/4afd4986-2af9-41f0-b719-488d744a1782) [0001410578-24-000865.rtf](/static-files/4dcb22a4-c4b9-45d5-8a20-1467fa942b93) [0001410578-24-000865.xls](/static-files/c91a17b1-5a66-461a-8ecc-e29c964baf09) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/10-q/0001410578-24-000865) [View HTML](/node/11051/html)  \nMay 15, 2024 | [8-K](/sec-filings/sec-filing/8-k/0001104659-24-062001) | Report of unscheduled material events or corporate event |  [0001104659-24-062001.pdf](/static-files/072b7487-3746-43d3-8922-5260f819cc10) [0001104659-24-062001.rtf](/static-files/050149ce-9545-41cb-9f03-2711e1166922) [0001104659-24-062001.xls](/static-files/d62d092b-cbbe-44a6-8e38-d673e7a33a9c) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/8-k/0001104659-24-062001) [View HTML](/node/11066/html)  \n  \nDisplaying 1 - 10 of 792 results\n\nData provided by [Kaleidoscope](https://www.kscope.io).\n\n[](#top \"Back to Top\")\n"
        },
        {
          "title": "Quarterly Results",
          "url": "https://ir.markertherapeutics.com/financials-filings/quarterly-results",
          "content": "[ Skip to main navigation ](#main-menu)\n\n  * [Contact Us](https://markertherapeutics.com/our-company/contact-us/)\n  * [](https://twitter.com/intent/tweet?text=Our Company http://newsite.markertherapeutics.com/our-company/overview/ \"Tweet This\")\n  * [](https://www.linkedin.com/company/marker-therapeutics \"Connect on LinkedIn\")\n\n\n\n![About Marker Therapeutics](/sites/g/files/knoqqb58336/themes/site/nir_pid3888/dist/images/subpage-header-ir-min.jpg)\n\nInvestors/Media\n\nQuarterly Results\n\n# Quarterly Results\n\n[Show all](#)\n\n## 2024\n\nThird Quarter\n\n  * [Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates](/news-releases/news-release-details/marker-therapeutics-reports-third-quarter-2024-financial-results)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001410578-24-001978)\n\n\n\n\nSecond Quarter\n\n  * [Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates](/news-releases/news-release-details/marker-therapeutics-reports-second-quarter-2024-financial)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001410578-24-001454)\n\n\n\n\nFirst Quarter\n\n  * [Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates](/news-releases/news-release-details/marker-therapeutics-reports-first-quarter-2024-financial-results)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001410578-24-000865)\n\n\n\n\n## 2023\n\nFourth Quarter\n\n  * [Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results](/news-releases/news-release-details/marker-therapeutics-reports-year-end-2023-corporate-and)\n\n  * [Form 10-K](/sec-filings/sec-filing/10-k/0001410578-24-000297)\n\n\n\n\nThird Quarter\n\n  * [Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates](/news-releases/news-release-details/marker-therapeutics-reports-third-quarter-2023-financial-results)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001410578-23-002307)\n\n\n\n\nSecond Quarter\n\n  * [Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update](/news-releases/news-release-details/marker-therapeutics-reports-second-quarter-2023-financial)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001410578-23-001875)\n\n\n\n\nFirst Quarter\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001410578-23-001217)\n\n\n\n\n## 2022\n\nFourth Quarter\n\n  * [Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results](/news-releases/news-release-details/marker-therapeutics-reports-fiscal-year-2022-corporate-and)\n\n  * [Form 10-K](/sec-filings/sec-filing/10-k/0001410578-23-000324)\n\n\n\n\nThird Quarter\n\n  * [Marker Therapeutics Reports Q3 2022 Operating and Financial Results](/news-releases/news-release-details/marker-therapeutics-reports-q3-2022-operating-and-financial)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001410578-22-003131)\n\n\n\n\nSecond Quarter\n\n  * [Marker Therapeutics Reports Q2 2022 Operating and Financial Results](/news-releases/news-release-details/marker-therapeutics-reports-q2-2022-operating-and-financial)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001410578-22-002292)\n\n\n\n\nFirst Quarter\n\n  * [Marker Therapeutics Reports Q1 2022 Operating and Financial Results](/news-releases/news-release-details/marker-therapeutics-reports-q1-2022-operating-and-financial)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001410578-22-001389)\n\n\n\n\n## 2021\n\nFourth Quarter\n\n  * [Marker Therapeutics Reports Fiscal Year 2021 Operating and Financial Results](/news-releases/news-release-details/marker-therapeutics-reports-fiscal-year-2021-operating-and)\n\n  * [Form 10-K](/sec-filings/sec-filing/10-k/0001410578-22-000418)\n\n\n\n\nThird Quarter\n\n  * [Marker Therapeutics Reports Third Quarter 2021 Operating and Financial Results](/news-releases/news-release-details/marker-therapeutics-reports-third-quarter-2021-operating-and)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001410578-21-000089)\n\n\n\n\nSecond Quarter\n\n  * [Marker Therapeutics Reports Second Quarter 2021 Operating and Financial Results](/news-releases/news-release-details/marker-therapeutics-reports-second-quarter-2021-operating-and)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001104659-21-102826)\n\n\n\n\nFirst Quarter\n\n  * [Marker Therapeutics First Quarter 2021 Financial and Operating Results](/events/event-details/marker-therapeutics-first-quarter-2021-financial-and-operating-results)\n\n  * [Marker Therapeutics Reports First Quarter 2021 Operating and Financial Results](/news-releases/news-release-details/marker-therapeutics-reports-first-quarter-2021-operating-and)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001104659-21-065131)\n\n\n\n\n## 2020\n\nFourth Quarter\n\n  * [Marker Therapeutics Reports Fiscal Year 2020 Operating and Financial Results](/news-releases/news-release-details/marker-therapeutics-reports-fiscal-year-2020-operating-and)\n\n  * [Form 10-K](/sec-filings/sec-filing/10-k/0001104659-21-033855)\n\n\n\n\nThird Quarter\n\n  * [Marker Therapeutics Third Quarter 2020 Financial and Operating Results](/events/event-details/marker-therapeutics-third-quarter-2020-financial-and-operating-results)\n\n  * [Marker Therapeutics Reports Third Quarter 2020 Operating and Financial Results](/news-releases/news-release-details/marker-therapeutics-reports-third-quarter-2020-operating-and)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001104659-20-123055)\n\n\n\n\nSecond Quarter\n\n  * [Marker Therapeutics Reports Second Quarter 2020 Operating and Financial Results](/news-releases/news-release-details/marker-therapeutics-reports-second-quarter-2020-operating-and)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001104659-20-092706)\n\n\n\n\nFirst Quarter\n\n  * [Marker Therapeutics Reports First Quarter 2020 Operating and Financial Results](/news-releases/news-release-details/marker-therapeutics-reports-first-quarter-2020-operating-and)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001104659-20-059515)\n\n\n\n\n## 2019\n\nFourth Quarter\n\n  * [Marker Therapeutics Reports Full Year 2019 Operating and Financial Results](/news-releases/news-release-details/marker-therapeutics-reports-full-year-2019-operating-and)\n\n  * [Form 10-K](/sec-filings/sec-filing/10-k/0001104659-20-032463)\n\n\n\n\nThird Quarter\n\n  * [Marker Therapeutics Reports Third Quarter 2019 Operating and Financial Results](/news-releases/news-release-details/marker-therapeutics-reports-third-quarter-2019-operating-and)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001104659-19-062594)\n\n\n\n\nSecond Quarter\n\n  * [Marker Therapeutics Reports Second Quarter 2019 Operating and Financial Results](/news-releases/news-release-details/marker-therapeutics-reports-second-quarter-2019-operating-and)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001144204-19-038714)\n\n\n\n\nFirst Quarter\n\n  * [Marker Therapeutics Reports First Quarter 2019 Operating and Financial Results](/news-releases/news-release-details/marker-therapeutics-reports-first-quarter-2019-operating-and)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001144204-19-025316)\n\n\n\n\n[](#top \"Back to Top\")\n"
        },
        {
          "title": "Annual Reports",
          "url": "https://ir.markertherapeutics.com/financials-filings/annual-reports-proxies",
          "content": "[ Skip to main navigation ](#main-menu)\n\n  * [Contact Us](https://markertherapeutics.com/our-company/contact-us/)\n  * [](https://twitter.com/intent/tweet?text=Our Company http://newsite.markertherapeutics.com/our-company/overview/ \"Tweet This\")\n  * [](https://www.linkedin.com/company/marker-therapeutics \"Connect on LinkedIn\")\n\n\n\n![About Marker Therapeutics](/sites/g/files/knoqqb58336/themes/site/nir_pid3888/dist/images/subpage-header-ir-min.jpg)\n\nInvestors/Media\n\nAnnual Reports & Proxies\n\n# Annual Reports & Proxies\n\n## Annual Reports\n\n[Filing date ](?field_nir_sec_form_group_target_id%5B471%5D=471&order=field_nir_sec_date_filed&sort=asc \"sort by Filing date\") | View  \n---|---  \nApr 26, 2024 | [View HTML](/node/11046/html) [0001104659-24-052923.pdf](/static-files/847d5b5a-cda5-4a89-92aa-f0cd8e305dae) [0001104659-24-052923.rtf](/static-files/44a62c68-e6a9-4bff-9de2-db57448e4869)  \nMar 26, 2024 | [View HTML](/node/11026/html) [0001410578-24-000297.pdf](/static-files/b1675741-3e60-4f3f-8334-6069069ce2bc) [0001410578-24-000297.rtf](/static-files/2023f4ff-327e-4470-b491-a8ca357c5f00) [0001410578-24-000297.xls](/static-files/c6efdbdf-5661-45ac-8b79-363e05aaa0f5) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/10-k/0001410578-24-000297)  \nApr 28, 2023 | [View HTML](/node/10736/html) [0001104659-23-052941.pdf](/static-files/63c24161-6568-479d-91a1-d07697afbef7) [0001104659-23-052941.rtf](/static-files/4b4d228d-26cc-4c85-95df-ad4561b61c25)  \nMar 22, 2023 | [View HTML](/node/10701/html) [0001410578-23-000324.pdf](/static-files/67360aeb-8f75-4969-b96b-069e4d0a6e38) [0001410578-23-000324.rtf](/static-files/73b00c63-4c42-4a2a-bdea-56a1502db86a) [0001410578-23-000324.xls](/static-files/83907600-cad3-4acd-ac0b-009f40253f4b) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/10-k/0001410578-23-000324)  \nMar 17, 2022 | [View HTML](/node/10371/html) [0001410578-22-000418.pdf](/static-files/6489ee46-f12f-4b2e-8c5b-70e3858bd3ec) [0001410578-22-000418.rtf](/static-files/0026ebc3-aed8-460a-b916-62ddd0b39743) [0001410578-22-000418.xls](/static-files/9547a5d6-4b96-459e-abe7-2fc9ecd8e69e) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/10-k/0001410578-22-000418)  \nMar 9, 2021 | [View HTML](/node/8721/html) [0001104659-21-033855.pdf](/static-files/0ed44ea3-8be3-4c9d-aadf-69e874086777) [0001104659-21-033855.rtf](/static-files/f8dca634-6079-4107-8cb9-9f80d4afec33) [0001104659-21-033855.xls](/static-files/61be5bdc-932d-448a-bad1-c87dd8ba9789) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/10-k/0001104659-21-033855)  \nMar 12, 2020 | [View HTML](/node/8406/html) [0001104659-20-032463.pdf](/static-files/1719f74f-89f0-4750-a2cb-52d437625b6c) [0001104659-20-032463.rtf](/static-files/476df109-397c-4c3d-acaf-92577529b320) [0001104659-20-032463.xls](/static-files/d4d602d7-859b-4f85-b4d4-2d53febafac0) [EX-101.INS - XBRL INSTANCE DOCUMENT](/sec-filings/sec-filing/10-k/0001104659-20-032463)  \nMar 15, 2019 | [View HTML](/node/8221/html) [0001144204-19-014350.pdf](/static-files/759eae42-bf39-4c2d-98b5-3b7fbe11b46f) [0001144204-19-014350.rtf](/static-files/715a24a0-335d-41ce-b5e7-a62df20b99e8) [0001144204-19-014350.xls](/static-files/2f5774c3-cafa-4a95-a942-14c3fa23cf23) [EX-101.INS - XBRL INSTANCE DOCUMENT](/sec-filings/sec-filing/10-k/0001144204-19-014350)  \nMar 23, 2018 | [View HTML](/node/7826/html) [0001144204-18-016734.pdf](/static-files/8c64fe47-8f33-4308-8a6b-ac8674636049) [0001144204-18-016734.rtf](/static-files/796a1ccd-9a9f-4872-9ed5-bdb5e2c3f190) [0001144204-18-016734.xls](/static-files/06c47e74-cb59-4f43-bb1b-0fc07308b087) [EX-101.INS - XBRL INSTANCE DOCUMENT](/sec-filings/sec-filing/10-k/0001144204-18-016734)  \nMar 14, 2017 | [View HTML](/node/7676/html) [0001144204-17-014490.pdf](/static-files/873d2a85-b3ee-44a4-a4ef-1222afd32fd3) [0001144204-17-014490.rtf](/static-files/8a8fb338-8525-4163-98fa-3fab13a04710) [0001144204-17-014490.xls](/static-files/ff6dae9a-b5f9-473a-8217-4c7187025157) [EX-101.INS - XBRL INSTANCE DOCUMENT](/sec-filings/sec-filing/10-k/0001144204-17-014490)  \nApr 14, 2016 | [View HTML](/node/7471/html) [0001193125-16-541539.pdf](/static-files/5ad659c5-4414-4fa6-83bd-1cf38583a139) [0001193125-16-541539.rtf](/static-files/eb98dc26-6a0b-4cdd-9f3c-2701504a3e23) [0001193125-16-541539.xls](/static-files/6536231b-2cfd-473d-a20d-ef818d6a3248) [EX-101.INS - XBRL INSTANCE DOCUMENT](/sec-filings/sec-filing/10-k/0001193125-16-541539)  \nMar 31, 2016 | [View HTML](/node/7446/html) [0001193125-16-525058.pdf](/static-files/f7d78318-9812-46e3-9fb2-71d44cd3d167) [0001193125-16-525058.rtf](/static-files/38e00c11-7c3d-446d-9821-f16a42996611) [0001193125-16-525058.xls](/static-files/008f4cd6-a414-4c91-a04c-3c969a40472c)  \nApr 15, 2015 | [View HTML](/node/7196/html) [0001424884-15-000039.pdf](/static-files/410a1c4f-973e-4248-a7b2-c54467115331) [0001424884-15-000039.rtf](/static-files/80f8c8bd-1937-40c5-9ff6-194cd7c5f26f) [0001424884-15-000039.xls](/static-files/a73112ee-3a38-411e-9c3e-16a3dd5f00f6) [EX-101.INS - ](/sec-filings/sec-filing/10-k/0001424884-15-000039)  \nApr 17, 2014 | [View HTML](/node/7051/html) [0001424884-14-000048.pdf](/static-files/b601dd8c-6dfe-4912-b911-72cf5667311d) [0001424884-14-000048.rtf](/static-files/bb6194d8-d947-421a-be96-c98ca0b6ad79) [0001424884-14-000048.xls](/static-files/53dafd34-e4fb-4e20-96e1-1c0d57b0aee7) [EX-101.INS - ](/sec-filings/sec-filing/10-ka/0001424884-14-000048)  \nApr 15, 2014 | [View HTML](/node/7046/html) [0001424884-14-000046.pdf](/static-files/d11c94af-2ea9-41da-93a1-a13478a6f13e) [0001424884-14-000046.rtf](/static-files/2c355410-1bce-4764-901f-f355729e9159) [0001424884-14-000046.xls](/static-files/1d78f24e-8ea3-4bb4-a9a0-4b237d8f9747)  \nApr 1, 2014 | [View HTML](/node/7041/html) [0001424884-14-000037.pdf](/static-files/2120be48-6d70-40db-af7d-e50a03aa4388) [0001424884-14-000037.rtf](/static-files/e85a48c1-66f7-4daf-ad9d-5abb92ed654c) [0001424884-14-000037.xls](/static-files/284777e6-05a7-48da-8ed6-df3d127b5852)  \nMay 15, 2013 | [View HTML](/node/6966/html) [0001554757-13-000319.pdf](/static-files/1edf7c3e-b3d2-458a-b581-8f0f5f02162b) [0001554757-13-000319.rtf](/static-files/68d5124c-d736-4c56-9b71-c4a41b35ab88) [0001554757-13-000319.xls](/static-files/153144c7-c5b9-483e-9aa7-e03221877540) [EX-101.INS - XBRL INSTANCE FILE](/sec-filings/sec-filing/10-k/0001554757-13-000319)  \nApr 2, 2013 | [View HTML](/node/6956/html) [0001554757-13-000191.pdf](/static-files/145031ce-4f8f-4271-a4fc-9f3edf44da0a) [0001554757-13-000191.rtf](/static-files/602f3da0-f1db-4590-b7a1-b298beaba68e) [0001554757-13-000191.xls](/static-files/43151752-55c5-40d8-b365-f5475262b862)  \nMar 30, 2012 | [View HTML](/node/9841/html) [0001424884-12-000021.pdf](/static-files/7bc6b207-806b-416d-aae5-fa87af0ca214) [0001424884-12-000021.rtf](/static-files/bdd62383-8395-4746-b317-59e0fd170f17) [0001424884-12-000021.xls](/static-files/455fce58-74c6-4710-af62-c84499c39208)  \nApr 15, 2010 | [View HTML](/node/9801/html) [0001424884-10-000040.pdf](/static-files/1c89ee79-78ff-4ed2-b172-a19865339bb5) [0001424884-10-000040.rtf](/static-files/5d6bc17c-938a-4c6d-af5c-f0a6208dcb76) [0001424884-10-000040.xls](/static-files/121c6760-5303-4ac4-a6e4-900a053a1020)  \nApr 1, 2010 | [View HTML](/node/9691/html) [0001183740-10-000161.pdf](/static-files/4d5e36c8-94d3-4b69-ae2b-fb71c14f808a) [0001183740-10-000161.rtf](/static-files/68b1cdfc-3563-47f1-99d7-47c3c7f96f32) [0001183740-10-000161.xls](/static-files/bb5a5831-ae6d-470a-a4e6-bfe91efc59a2)  \nMay 8, 2009 | [View HTML](/node/9726/html) [0001424884-09-000033.pdf](/static-files/3d931726-577a-41ad-b615-83a9c7af3405) [0001424884-09-000033.rtf](/static-files/e5c2715a-2e26-4dc9-aea0-fccba2e8b8f4) [0001424884-09-000033.xls](/static-files/a904d3ce-6318-4e1e-bf07-1eddd8945ebd)  \nMar 31, 2009 | [View HTML](/node/9671/html) [0001183740-09-000136.pdf](/static-files/faf46fa7-6e53-432b-8be5-8783f833d05c) [0001183740-09-000136.rtf](/static-files/750de373-df54-49f8-83cf-4acb8d6a7d96) [0001183740-09-000136.xls](/static-files/efdcc008-2089-4233-aec4-9b6d53f3dce7)  \nAug 26, 2008 | [View HTML](/node/9631/html) [0001183740-08-000466.pdf](/static-files/834a1151-fa7e-4e4b-b771-3b0bf4eab93d) [0001183740-08-000466.rtf](/static-files/8da008b7-9e97-4fb2-8019-b293b0b8fa56) [0001183740-08-000466.xls](/static-files/1514e219-0116-4783-9344-32324c34c50d)  \nApr 14, 2008 | [View HTML](/node/9436/html) [0001171520-08-000222.pdf](/static-files/2df10f7e-ecb9-463b-9d98-c3c2b356d77a) [0001171520-08-000222.rtf](/static-files/9e3303f9-88b3-40fd-a168-c7a7f0fe36fc) [0001171520-08-000222.xls](/static-files/4c15bde0-089d-4eb2-be47-26ee0762e671)  \nMar 31, 2008 | [View HTML](/node/9431/html) [0001171520-08-000195.pdf](/static-files/e5f7adf9-f9e1-45f3-97c8-227a909842f9) [0001171520-08-000195.rtf](/static-files/0190f7d6-1819-410a-a290-8282ab465d6e)  \nApr 18, 2007 | [View HTML](/node/9536/html) [0001183740-07-000209.pdf](/static-files/eed7ea36-5c4e-4178-9f95-9f53f671f652) [0001183740-07-000209.rtf](/static-files/cfa4e08f-e2de-464d-880e-86e45942b5ee) [0001183740-07-000209.xls](/static-files/31e9f42e-93c7-4125-a0c8-333242bb751b)  \nApr 2, 2007 | [View HTML](/node/9531/html) [0001183740-07-000162.pdf](/static-files/f0df892b-a33e-4760-aa56-384d961349c6) [0001183740-07-000162.rtf](/static-files/a51584ec-4f6d-4e65-a4a3-c73a7bf8a6da) [0001183740-07-000162.xls](/static-files/192d7573-3b70-4492-b949-0c092db89efd)  \nMay 1, 2006 | [View HTML](/node/9486/html) [0001183740-06-000069.pdf](/static-files/878076c3-06aa-490f-88ae-2f045a688090) [0001183740-06-000069.rtf](/static-files/867c8d06-1ac1-44a8-a4ee-8d9427fcd20f) [0001183740-06-000069.xls](/static-files/f8c3c65e-2567-4b2e-af40-df6a72651481)  \nApr 19, 2006 | [View HTML](/node/9481/html) [0001183740-06-000067.pdf](/static-files/428bacdd-72e3-49f6-aae9-67572c0ddf11) [0001183740-06-000067.rtf](/static-files/b635164b-8093-4b80-89fd-c8a55d963f03) [0001183740-06-000067.xls](/static-files/040910c2-d554-420c-947a-a555b191b744)  \nMar 29, 2006 | [View HTML](/node/9476/html) [0001183740-06-000063.pdf](/static-files/dd1fd6b2-26aa-4394-8659-71d32e822930) [0001183740-06-000063.rtf](/static-files/ad94f1d6-22e2-4ddc-8459-49c2d42d5e17) [0001183740-06-000063.xls](/static-files/303ec9d4-9d39-46a5-a5a2-b865ec6bcddb)  \nApr 29, 2005 | [View HTML](/node/6241/html) [0000950134-05-008565.pdf](/static-files/7145216e-d6bb-4116-9f9e-4fbfbcf6496c) [0000950134-05-008565.rtf](/static-files/c117cc1e-24a4-437e-a29b-ddc9362673a6) [0000950134-05-008565.xls](/static-files/8bfc369e-1726-4323-bb97-7db73e477d52)  \nApr 15, 2005 | [View HTML](/node/6236/html) [0000950134-05-007541.pdf](/static-files/5cc49bf5-6f1e-43c1-b0fc-93120ccee006) [0000950134-05-007541.rtf](/static-files/cad9d876-5205-4579-af3b-d257cdbd1cd9) [0000950134-05-007541.xls](/static-files/2700ca44-5954-4227-ac0c-6a27f61c6cc3)  \nApr 1, 2005 | [View HTML](/node/6231/html) [0000950134-05-006676.pdf](/static-files/9bc8ef6d-b06b-4d0f-bcbe-acf89752158c) [0000950134-05-006676.rtf](/static-files/3528ba33-ede8-40e2-b4f0-710084864db6) [0000950134-05-006676.xls](/static-files/ec8dbe0d-7342-4f7c-a962-e15c7b84b349)  \nApr 14, 2004 | [View HTML](/node/9336/html) [0001092306-04-000268.pdf](/static-files/2e17d6c3-c55d-4b97-b2c2-02b0f0f4a354) [0001092306-04-000268.rtf](/static-files/9b971267-1bce-48ab-9bc2-2586616eeb88)  \nMar 31, 2004 | [View HTML](/node/9331/html) [0001092306-04-000202.pdf](/static-files/03bf0ebc-1f20-4193-9df7-bc2bd1f569c9) [0001092306-04-000202.rtf](/static-files/5cbaa4fa-3ceb-4281-8ccc-ed1687fc1ec6)  \nApr 15, 2003 | [View HTML](/node/9196/html) [0001050502-03-000335.pdf](/static-files/8a03d756-18fa-45a1-849f-73c8c48d189c) [0001050502-03-000335.rtf](/static-files/ab3a1c04-4586-4478-aa44-9780f1dbc9c8)  \nApr 1, 2003 | [View HTML](/node/9191/html) [0001050502-03-000285.pdf](/static-files/dba404cd-959e-4470-9304-def776cd7a8f) [0001050502-03-000285.rtf](/static-files/6c223f07-d15c-4827-a57b-812850f16612)  \nMar 28, 2002 | [View HTML](/node/9391/html) [0001108890-02-000130.pdf](/static-files/894fd4bf-ea1c-459f-828a-ce48f48f2d27) [0001108890-02-000130.rtf](/static-files/3d4daaa7-c5ba-43f4-b224-e7b754d5da7d)  \nApr 17, 2001 | [View HTML](/node/9216/html) [0001092306-01-500007.pdf](/static-files/782b942d-31f4-419f-b203-e006c78af843) [0001092306-01-500007.rtf](/static-files/1256493c-1a21-4398-aa38-da1bb3f9757a)  \nApr 2, 2001 | [View HTML](/node/9211/html) [0001092306-01-000105.pdf](/static-files/44e70286-311d-4f99-ba58-f15565dccdb8) [0001092306-01-000105.rtf](/static-files/9f52261d-7a7a-410b-999c-0b39156002c7)  \nApr 13, 2000 | [View HTML](/node/6196/html) [0000912282-00-000128.pdf](/static-files/3b1816c3-eece-4ca5-9257-235e1006dbca) [0000912282-00-000128.rtf](/static-files/898cd82a-e604-4fc5-b0ba-011a5f98724a) [0000912282-00-000128.xls](/static-files/3b82eee2-64a9-4633-8f8c-e13eea2cb7cb)  \nMar 31, 2000 | [View HTML](/node/6191/html) [0000912282-00-000116.pdf](/static-files/2fb9f1c6-f3ab-4c62-9c8c-5dd70854b641) [0000912282-00-000116.rtf](/static-files/67db7a9f-28dd-4692-9c59-8555f35c9166)  \n  \n## Proxy Statements\n\n[Filing date ](?field_nir_sec_form_group_target_id%5B491%5D=491&order=field_nir_sec_date_filed&sort=asc \"sort by Filing date\") | View  \n---|---  \nApr 26, 2024 | [View HTML](/node/11041/html) [0001104659-24-052914.pdf](/static-files/1d3da593-a113-4584-b0da-6e35425ddc88) [0001104659-24-052914.rtf](/static-files/e2351359-7a72-49ec-9d4f-a58bb35c324c) [0001104659-24-052914.xls](/static-files/72c15b6d-5eba-4d15-a4f8-5008cbdfc1e4)  \nApr 28, 2023 | [View HTML](/node/10731/html) [0001104659-23-052923.pdf](/static-files/bb1f033e-1cbb-433a-819b-6a135c4c0916) [0001104659-23-052923.rtf](/static-files/7066d10b-e36d-4ea7-9fd5-605f243fdf45) [0001104659-23-052923.xls](/static-files/197df0b3-e6e1-4b47-a461-f1c79316bcc6)  \nApr 15, 2022 | [View HTML](/node/10421/html) [0001104659-22-046490.pdf](/static-files/b6c542eb-7769-4acc-9fcd-ce7e43f3e15c) [0001104659-22-046490.rtf](/static-files/0746e55d-40e9-4cbb-80a3-acd296e07f4f) [0001104659-22-046490.xls](/static-files/318d18b5-9a22-44ed-9ab5-d5c19de5a4a9)  \nApr 6, 2022 | [View HTML](/node/10416/html) [0001104659-22-043219.pdf](/static-files/c42fce1b-675d-4758-86fb-25f3fccba2c9) [0001104659-22-043219.rtf](/static-files/d71a0fd2-ef11-40d1-b136-db5e5bafd30c) [0001104659-22-043219.xls](/static-files/0e209e71-a8c4-4faa-af3c-7aba84ca2555)  \nMay 5, 2021 | [View HTML](/node/8901/html) [0001104659-21-061740.pdf](/static-files/5ba36807-83c6-4e1b-b7ad-153250c47a18) [0001104659-21-061740.rtf](/static-files/a52897dd-77dc-4549-bf94-a48aba75bbc4) [0001104659-21-061740.xls](/static-files/9108e14a-66a5-48a2-918e-8ff1d8fdcc40)  \nApr 23, 2021 | [View HTML](/node/8876/html) [0001104659-21-054487.pdf](/static-files/24739bde-a1e5-4be0-95fa-729c0817ee4e) [0001104659-21-054487.rtf](/static-files/b0958b96-5cfa-441b-8ef6-68b5da7474e2)  \nApr 23, 2021 | [View HTML](/node/8871/html) [0001104659-21-054483.pdf](/static-files/dd48e273-4700-4ccf-84ce-b09a855fe0d6) [0001104659-21-054483.rtf](/static-files/94f22ec0-b493-4028-a0fc-04221d7f4342) [0001104659-21-054483.xls](/static-files/a45f48c7-4328-4358-a19a-f758f0171928)  \nApr 17, 2020 | [View HTML](/node/8471/html) [0001104659-20-048175.pdf](/static-files/6c93e42e-cff7-4f54-b247-082a564fc519) [0001104659-20-048175.rtf](/static-files/cdc5cb3b-8fcb-4698-ab32-70dc466378c8) [0001104659-20-048175.xls](/static-files/fad76a58-366b-48df-b0a4-82c151e32301)  \nMar 28, 2019 | [View HTML](/node/8231/html) [0001144204-19-016692.pdf](/static-files/40f1284c-6e78-45de-9692-27db8fb6b2de) [0001144204-19-016692.rtf](/static-files/3899a848-3028-4346-ad98-7d6041c40a11) [0001144204-19-016692.xls](/static-files/dadb6078-5d70-485c-97e0-c0379be5c0e2)  \nMar 28, 2019 | [View HTML](/node/8236/html) [0001144204-19-016699.pdf](/static-files/baf6c0b4-0d8b-4e12-b723-12202a8f758e) [0001144204-19-016699.rtf](/static-files/c0143ad2-ee34-4748-86f5-e6883ed9214f) [0001144204-19-016699.xls](/static-files/53206ae8-87cf-4d8f-83bf-8adcd7ce3a88)  \nSep 7, 2018 | [View HTML](/node/7911/html) [0001571049-18-000475.pdf](/static-files/e252524e-fb2d-4daf-9222-dd798bbbe44f) [0001571049-18-000475.rtf](/static-files/586846a7-c92e-4715-a679-77c5fd84f954) [0001571049-18-000475.xls](/static-files/5511890a-d80b-4799-b0e6-e31770c015f0)  \nAug 8, 2018 | [View HTML](/node/7896/html) [0001144204-18-042863.pdf](/static-files/ae2a34f2-2afe-41fa-9ea9-c8219f5fbf18) [0001144204-18-042863.rtf](/static-files/18820834-de0f-4e38-a73b-a9f9cbb30dfe) [0001144204-18-042863.xls](/static-files/3c496e62-19de-484a-9ea1-d241fa6309ff)  \nMay 15, 2018 | [View HTML](/node/7846/html) [0001144204-18-028371.pdf](/static-files/b0559f7f-f586-48ab-af7e-e773409f181d) [0001144204-18-028371.rtf](/static-files/f99e051a-bc68-4be1-89ff-66a9f1cb5c5b) [0001144204-18-028371.xls](/static-files/e79c9e56-6f27-4e4b-a96d-1089f4f17fdb)  \nJul 12, 2017 | [View HTML](/node/7711/html) [0001144204-17-036528.pdf](/static-files/7d5d0cc7-13ea-4525-96ab-91c195c86d50) [0001144204-17-036528.rtf](/static-files/4e25be94-6262-4e71-b610-5710bd7fad37) [0001144204-17-036528.xls](/static-files/0bc2a584-2933-43f8-a123-69104444a2c4)  \nJan 17, 2014 | [View HTML](/node/7021/html) [0001424884-14-000011.pdf](/static-files/44e65f5b-f7bd-4315-9a9d-f6878582b073) [0001424884-14-000011.rtf](/static-files/8b333db0-8f01-4ca5-a23c-0e744d5b4853) [0001424884-14-000011.xls](/static-files/b58499f7-cae2-4826-808b-a2ee06b25035)  \nJan 6, 2010 | [View HTML](/node/9781/html) [0001424884-10-000002.pdf](/static-files/585e94d4-1307-45cc-a4ef-00d4511d49d0) [0001424884-10-000002.rtf](/static-files/e8121769-c6ca-4311-8e0c-b338e9b383a5) [0001424884-10-000002.xls](/static-files/90198023-a92a-4434-b9e3-253b0426e1ff)  \nDec 30, 2008 | [View HTML](/node/9651/html) [0001183740-08-000691.pdf](/static-files/c50f0523-b9c2-4736-a7d1-34d9be495418) [0001183740-08-000691.rtf](/static-files/d6d917ba-1f37-4fd1-9d03-251a685edcda) [0001183740-08-000691.xls](/static-files/856b111f-107b-47e6-be77-9be41844a03c)  \nDec 10, 2008 | [View HTML](/node/9646/html) [0001183740-08-000648.pdf](/static-files/d85b55df-3e93-44c9-baeb-d47ab742614d) [0001183740-08-000648.rtf](/static-files/5d4a3c17-1d9b-44a0-81c9-f56f6d3e706a) [0001183740-08-000648.xls](/static-files/68d3bda6-f75d-48d9-b6b2-a5a22a1123b8)  \nMar 2, 2007 | [View HTML](/node/9526/html) [0001183740-07-000103.pdf](/static-files/f02d9533-8ede-4b51-9c69-3c6b94dbb01e) [0001183740-07-000103.rtf](/static-files/31396bcf-193d-434b-b1e2-d9d3f5fa6d87) [0001183740-07-000103.xls](/static-files/96a46ce6-fa57-4f9e-8ede-c01ea7744618)  \nFeb 16, 2007 | [View HTML](/node/9521/html) [0001183740-07-000082.pdf](/static-files/ca6f2228-011a-4153-80f8-32df1e830e7c) [0001183740-07-000082.rtf](/static-files/cac923d2-aca0-4c05-9af4-65576eb5f281) [0001183740-07-000082.xls](/static-files/e542fa8d-430b-4355-b644-8538ebe4bc80)  \nMar 26, 2004 | [View HTML](/node/9326/html) [0001092306-04-000175.pdf](/static-files/6657ac9c-bba2-4ce3-8cc9-52b62d62fbdb) [0001092306-04-000175.rtf](/static-files/6dbf58db-4590-4448-aad9-07fffdfb62a8)  \nMar 16, 2004 | [View HTML](/node/9321/html) [0001092306-04-000151.pdf](/static-files/df82e2c9-3263-41df-a41f-df74f49adb77) [0001092306-04-000151.rtf](/static-files/e96fe3cd-d027-401e-a855-0689a140a0dd)  \nMar 5, 2004 | [View HTML](/node/9316/html) [0001092306-04-000143.pdf](/static-files/b6b9bd81-e1c2-466b-a728-1e926cce9bc5) [0001092306-04-000143.rtf](/static-files/cb1bbd29-4897-472f-b6b9-3abfb21bf491)  \nJun 5, 2002 | [View HTML](/node/6471/html) [0001050502-02-000434.pdf](/static-files/40fcbe19-68e3-4e32-bdb8-92d479411505) [0001050502-02-000434.rtf](/static-files/8da0612c-f258-4c5a-8d1b-c8b6bc75c34f)  \nMay 31, 2002 | [View HTML](/node/6311/html) [0001000096-02-000342.pdf](/static-files/a6da673d-c45e-4e31-a606-c0afbb884b94) [0001000096-02-000342.rtf](/static-files/27249420-39b5-401d-bd94-ad61e4b2ff2d)  \nMay 8, 2001 | [View HTML](/node/6411/html) [0001050502-01-500046.pdf](/static-files/d92d37b1-d453-4f78-b75a-00ab73a9fcac) [0001050502-01-500046.rtf](/static-files/3b084b61-732c-44da-92de-3f65c04d535f)  \nMay 3, 2001 | [View HTML](/node/6406/html) [0001050502-01-500022.pdf](/static-files/978ea411-43ab-4be2-9200-9d9e20a5765b) [0001050502-01-500022.rtf](/static-files/4a09bd47-450f-4493-b290-db31740dd57e)  \nApr 27, 2001 | [View HTML](/node/6256/html) [0001000096-01-500049.pdf](/static-files/5ce761a1-ebe2-4401-9c8a-b932e486aa00) [0001000096-01-500049.rtf](/static-files/498e498b-380a-42c2-bfdf-d2a0385454e8)  \n  \n[](#top \"Back to Top\")\n"
        }
      ]
    },
    {
      "section_name": "Stock Information",
      "links": [
        {
          "title": "Stock Quote & Chart",
          "url": "https://ir.markertherapeutics.com/stock-information/stock-quote-chart",
          "content": "[ Skip to main navigation ](#main-menu)\n\n  * [Contact Us](https://markertherapeutics.com/our-company/contact-us/)\n  * [](https://twitter.com/intent/tweet?text=Our Company http://newsite.markertherapeutics.com/our-company/overview/ \"Tweet This\")\n  * [](https://www.linkedin.com/company/marker-therapeutics \"Connect on LinkedIn\")\n\n\n\n![About Marker Therapeutics](/sites/g/files/knoqqb58336/themes/site/nir_pid3888/dist/images/subpage-header-ir-min.jpg)\n\nInvestors/Media\n\nStock Quote & Chart\n\n# Stock Quote & Chart\n\n## Stock Quote\n\n    Change\n    Volume\n    Today's Open\n    Previous Close\n\n    Today's High\n    Today's Low\n    52 Week High\n    52 Week Low\n\n## Stock Chart\n\nMinimum 15 minutes delayed. Source: LSEG\n\n[](#top \"Back to Top\")\n"
        },
        {
          "title": "Historic Price Lookup",
          "url": "https://ir.markertherapeutics.com/stock-information/historic-price-lookup",
          "content": "[ Skip to main navigation ](#main-menu)\n\n  * [Contact Us](https://markertherapeutics.com/our-company/contact-us/)\n  * [](https://twitter.com/intent/tweet?text=Our Company http://newsite.markertherapeutics.com/our-company/overview/ \"Tweet This\")\n  * [](https://www.linkedin.com/company/marker-therapeutics \"Connect on LinkedIn\")\n\n\n\n![About Marker Therapeutics](/sites/g/files/knoqqb58336/themes/site/nir_pid3888/dist/images/subpage-header-ir-min.jpg)\n\nInvestors/Media\n\nHistoric Price Lookup\n\n# Historic Price Lookup\n\nLookup Month JanuaryFebruaryMarchAprilMayJuneJulyAugustSeptemberOctoberNovemberDecember\n\nDecember\n\nLookup Day 12345678910111213141516171819202122232425262728293031\n\n3\n\nLookup Year 2018201920202021202220232024\n\n2024\n\nLeave this field blank\n\n## Week of December 2, 2024\n\nDate Requested | Closing Price | Volume | Split Adjustment Factor | Open Price | Day High | Day Low  \n---|---|---|---|---|---|---  \nDec 2, 2024 | $3.64 | 17,767 | 1:1 | $3.41 | $3.64 | $3.32  \n  \nNOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date shown. The Split Adjustment Factor is a cumulative factor which encapsulates all splits since the date shown. The closing price is not necessarily indicative of future price performance.\n\nMinimum 15 minutes delayed. Source: LSEG\n\n[](#top \"Back to Top\")\n"
        },
        {
          "title": "Analyst Coverage",
          "url": "https://ir.markertherapeutics.com/stock-information/analyst-coverage",
          "content": "[ Skip to main navigation ](#main-menu)\n\n  * [Contact Us](https://markertherapeutics.com/our-company/contact-us/)\n  * [](https://twitter.com/intent/tweet?text=Our Company http://newsite.markertherapeutics.com/our-company/overview/ \"Tweet This\")\n  * [](https://www.linkedin.com/company/marker-therapeutics \"Connect on LinkedIn\")\n\n\n\n![About Marker Therapeutics](/sites/g/files/knoqqb58336/themes/site/nir_pid3888/dist/images/subpage-header-ir-min.jpg)\n\nInvestors/Media\n\nAnalyst Coverage\n\n# Analyst Coverage\n\nCompany | Analyst   \n---|---  \nLadenburg |  Aydin Huseynov, MD, CFA   \n  \nMarker Therapeutics, Inc. is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding Marker Therapeutics, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Marker Therapeutics, Inc. or its management. Marker Therapeutics, Inc. does not by its reference or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.\n\n[](#top \"Back to Top\")\n"
        },
        {
          "title": "IRS Form 8937",
          "url": "https://ir.markertherapeutics.com/stock-information/irs-form-8937",
          "content": "[ Skip to main navigation ](#main-menu)\n\n  * [Contact Us](https://markertherapeutics.com/our-company/contact-us/)\n  * [](https://twitter.com/intent/tweet?text=Our Company http://newsite.markertherapeutics.com/our-company/overview/ \"Tweet This\")\n  * [](https://www.linkedin.com/company/marker-therapeutics \"Connect on LinkedIn\")\n\n\n\n![About Marker Therapeutics](/sites/g/files/knoqqb58336/themes/site/nir_pid3888/dist/images/subpage-header-ir-min.jpg)\n\nInvestors/Media\n\nIRS Form 8937\n\n# IRS Form 8937\n\nJanuary 26, 2023\n\n[IRS Form 8937](/static-files/e6a7ca7c-ab1e-4103-9c7c-1867662b8334 \"Marker Therapeutics, Inc. IRS Form 8937.pdf\") 274.9 KB\n\n[](#top \"Back to Top\")\n"
        }
      ]
    }
  ]
}